STOCK TITAN

Pluri Inc - PLUR STOCK NEWS

Welcome to our dedicated news page for Pluri (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pluri's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pluri's position in the market.

Rhea-AI Summary
Pluri Inc. unveils a groundbreaking method for expanding immune cells using proprietary technology, securing a new U.S. patent. The innovative 3D cell expansion technology mimics the natural lymph node environment, ensuring the integrity and functionality of immune cells. This advancement positions Pluri at the forefront of allogeneic cell therapy, promising significant therapeutic advancements and commercial success. The estimated total addressable market for immune cell engineering is projected to grow to $11.66 billion by 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces participation in various conferences to showcase its innovative cell-based solutions and business verticals. The company's leadership will present at MIW, ATiO Conference 2024, Biomed Israel, and Bio International Convention, highlighting advancements in 3D cell expansion technology, cell-based coffee business, and PLX-PAD therapy product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.39%
Tags
conferences
-
Rhea-AI Summary
Pluri Inc. announces a reverse share split of its common shares at a ratio of 1-for-8, reducing outstanding shares from 41,816,959 to approximately 5,227,120. The split will not impact ownership or voting power, with fractional shares rounded up. Equiniti Trust Company, will act as the exchange agent for the reverse split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.75%
Tags
Rhea-AI Summary
Pluri Inc. addresses price instability in the coffee industry highlighted in the International Coffee Organization's 2024 Market Report by introducing cell-based coffee production, offering a sustainable and innovative solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces participation in key biotech conferences to showcase its innovative solutions for global wellbeing and sustainability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
-
Rhea-AI Summary
Pluri Inc. announces a manufacturing agreement between PluriCDMO™ and Remedy Cell Ltd for the production of the drug candidate RC-0315 to treat Idiopathic Pulmonary Fibrosis. The agreement aims to support Remedy Cell in manufacturing a clinical-grade Working Cell Bank and GMP batches for their Phase Ib clinical trial. Remedy Cell's CEO expresses excitement for the partnership, emphasizing the need for innovative treatments in complex conditions like IPF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
Rhea-AI Summary
Pluri Inc. announces the approval of a new patent titled “A System for 3D Cultivation of Plant Cells and Methods of Use” that revolutionizes the agricultural technology landscape. This patent enhances Pluri's 3D bioreactor technology, enabling efficient cultivation of plant cells for various applications, including the production of sustainable cell-based coffee. The technology reduces water usage by 98% and growing area by 95%, addressing environmental concerns. With the global cellular agriculture market projected to reach $515 billion by 2030, Pluri's patented technology places it at the forefront of innovation in the agtech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
-
Rhea-AI Summary
Pluri Inc. appoints attorney James Roosevelt, Jr. to its Advisory Board, bringing expertise in public policy, health, and business matters. Mr. Roosevelt's background in healthcare leadership and advocacy will aid Pluri in advancing its mission of developing sustainable cell-based treatments for unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.77%
Tags
management
-
Rhea-AI Summary
Pluri Inc. announces significant advancements in its various divisions including PluriAgtech, PluriCDMO, PluriHealth, and PluriFood, with notable collaborations and partnerships. The company secured a $4.2 million contract with the U.S. NIH and formed a new partnership with Bar-Ilan University. A landmark collaboration with Tnuva Group is driving technology forward, attracting global interest.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
Rhea-AI Summary
Pluri Inc. announced the launch of its cell-based coffee business activity, aiming to revolutionize the traditional coffee industry by leveraging its proprietary 3D technology platform. The company's cell-based coffee is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production. Pluri's innovative product is estimated to reduce water usage by 98% and growing areas by 95%, thus preventing deforestation. The company aims to spin out its cell-based coffee as a new subsidiary focused on developing innovative products, technologies, and intellectual property for the coffee industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
none
Pluri Inc

Nasdaq:PLUR

PLUR Rankings

PLUR Stock Data

30.06M
3.16M
24.62%
10.7%
0.25%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Building No 5

About PLUR

pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi